07/2025
We are delighted to announce that Patrik Grandits has joined the Vaccentis AG Board of Directors!With almost…
06/2025
On June 17th we held our Annual General Meeting in Zürich. We presented our strategic…
06/2025
The Vaccentis roadshow with 8 Hours Ahead in Hong Kong and China in May 2025…
05/2025
Vaccentis is very pleased to announce the collaboration with Krems Bioanalytics! Together with our Head…
05/2025
It was a great opportunity for Vaccentis to present the company's focus areas in the…
04/2025
Great Vaccentis video recording with Reinhard Rosenberger and his team, with our Head of Research…
04/2025
Vaccentis CEO Martin Munte acknowledges the potential of a R&D hub in Vienna in oe24…
02/2025
Cancer vaccine from Austria: “Approval by 2029 realistic” Link: Krebsimpfstoff aus Österreich: "Zulassung bis 2029…
02/2025
Science that gives hope. New cancer treatment options are presented on World Cancer Day in…
01/2025
Our Head of R&D and CMO Ingrid Rauter met with Krems Bioanalytics to discuss key R&D projects for the…
01/2025
After a long time of research in the field of oncology immunotherapy major breakthrough developments…
12/2024
Our Head of R&D and Chief Medical Officer Ingrid Rauter and our CEO Martin Munte…
11/2024
We are very proud to share this article from the Austrian newspaper Kurier, in which the…
11/2024
Excellent review article on difficult to treat immunologic targets. Future tumour vaccine developments must also…
11/2024
Our Head of Research and Development, Dr Ingrid Rauter, talks in the Swiss magazine Sprechstunde…
